Myelodysplastic syndrome with t(9;11)(p22;q23) after treatment for B-cell acute lymphoblastic leukemia without epipodophyllotoxins

Masaru Kubota, Yasuko Hoshino, Hiraku Doi, Hideki Ueno, Yoshinobu Nishida, Haruyo Hirota, Yuichi Akiyama

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Secondary myelodysplastic syndrome (MDS) with t(9;11)(p22;q23) developed in a child after intensive treatment for B-cell acute lymphoblastic leukemia di-agnosed 12 months earlier. His chemotherapy had consisted mainly of cyclo-phosphamide and methotrexate, but no epipodophyllotoxins. The combination of MDS, the cytogenetic anomaly involving bands at 11 q23 and no previous exposure to epipodophyllotoxins represents a unique case of therapy- related leukemia.

Original languageEnglish
Pages (from-to)33-35
Number of pages3
JournalActa Haematologica
Volume92
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Keywords

  • Epipodophyllotoxin
  • Myelodysplastic syndrome
  • Therapy-related leukemia
  • t(9;11)(p22;q23)

Fingerprint

Dive into the research topics of 'Myelodysplastic syndrome with t(9;11)(p22;q23) after treatment for B-cell acute lymphoblastic leukemia without epipodophyllotoxins'. Together they form a unique fingerprint.

Cite this